Claims
- 1. A pharmaceutical preparation for reducing side effects during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone, said side effects including hot flashes, prostate enlargement and gynecomastia, said pharmaceutical preparation containing an effective amount of at least one active ingredient selected from the group comprising chemically modified derivatives of 17α-estradiol, chemically modified derivatives of 17β-estradiol and chemically modified derivatives of estriol.
- 2. A pharmaceutical preparation for reducing side effects during and/or after treatment with analogs or antagonists of gonadotropin-releasing hormone, said pharmaceutical preparation containing an effective amount of at least one active ingredient selected from the group consisting of 14α,15α-methylene-1,3,5(10),8-tetraene-3,17α-diol, 4-methylestra-1,3,5(10)-triene-1,17α-diol, 4-methylestra-1,3,5(10), 6-tetraene-1,17α-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17α-diol, ent-estradiol, 4-methylestra-1,3,5(10), 6-tetraene-1,17β-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17β-diol, 17α-4′-hydroxyphenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxyphenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxythiophenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylamino-phenoxymethyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylamino-phenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylaminophenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxy-phenylmethyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxyphenylmethyl-4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 17α-4′-hydroxyphenoxymethyl-4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 14β,15β-methylene-8-dehydroestradiol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17α-diol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17β-diol, 14α,15α-methylene-1,3,5(10),8-tetraene-3,17β-diol, 6-dehydroestriol and 9(11)-dehydroestriol.
- 3. The pharmaceutical preparation as defined in claim 2, wherein said at least one active ingredient is said 14α,15α-methylene-1,3,5(10),8-tetraene-3,17α-diol.
- 4. A method of reducing estrogen side effects resulting from treatment with analogs or antagonists of gonadotropin-releasing hormone in a human female, said method comprising administering to said female during and/or after said treatment an effective amount of at least one active ingredient selected from the group consisting of 14α,15α-methylene-1,3,5(10), 8-tetraene-3,17α-diol, 4-methylestra-1,3,5(10)-triene-1,17α-diol, 4-methylestra-1,3,5(10), 6-tetraene-1,17α-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17α-diol, ent-estradiol, 4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17β-diol, 17α-4′-hydroxyphenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxyphenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxythiophenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylamino-phenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylaminophenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxy-phenylmethyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxyphenyl-methyl-4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 17β-4′-hydroxyphenoxy-methyl-4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 14β,15β-methylene-8-dehydro-estradiol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17α-diol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17β-diol, 14α,15α-methylene-1,3,5(10),8-tetraene-3,17β-diol, 6-dehydroestriol and 9(11)-dehydroestriol.
- 5. The method as defined in claim 4, wherein said side effects are hot flashes.
- 6. The method as defined in claim 4, wherein said at least one active ingredient is said 14α,15α-methylene-1,3,5(10),8-tetraene-3,17α-diol.
- 7. A method of reducing estrogen side effects resulting from treatment with analogs or antagonists of gonadotropin-releasing hormone in a human male, said method comprising administering to said male during and/or after said treatment an effective amount of at least one active ingredient selected from the group consisting of 14α,15α-methylene-1,3,5(10),8-tetraene-3,17α-diol, 4-methylestra-1,3,5(10)-triene-1,17α-diol, 4-methylestra-1,3,5(10),6-tetraene-1,17α-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17α-diol, ent-estradiol, 4-methylestra-1,3,5(10), 6-tetraene-1,17β-diol, 4-methylestra-1,3,5(10),6,8-pentaene-1,17β-diol, 17α-4′-hydroxyphenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxyphenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-hydroxythiophenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylamino-phenoxy-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-4′-dimethylaminophenyl-methyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxy-phenylmethyl-4-methylestra-1,3,5(10)-triene-1,17β-diol, 17α-3′,5′-dimethyl-4′-hydroxyphenylmethyl-4-methylestra-1,3,5(10), 6-tetraene-1,17β-diol, 17α-4′-hydroxyphenoxymethyl-4-methylestra-1,3,5(10),6-tetraene-1,17β-diol, 14β,15β-methylene-8-dehydro-estradiol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17α-diol, 14β,15β-methylene-1,3,5(10),8-tetraene-3,17β-diol, 14α,15α-methylene-1,3,5(10),8-tetraene-3,17β-diol, 6-dehydroestriol and 9(11)-dehydroestriol.
- 8. The method as defined in claim 7, wherein said side effects include prostate enlargement and gynecomastia.
- 9. The method as defined in claim 7, wherein said at least one active ingredient is said 14α,15α-methylene-1,3,5(10), 8-tetraene-3,17α-diol.
CROSS-REFERENCES
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/291,385, now abandoned, which, in turn, claims the benefit of U. S. Provisional Patent Application, Ser. No. 60/081,791, filed Apr. 15, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60081791 |
Apr 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09291385 |
Apr 1999 |
US |
Child |
09891722 |
Jun 2001 |
US |